GWT-Tud GmbH
- Address
- Freiberger Strasse 33, Wilsdruffer Vorstadt/seevorstadt-West
Sponsor Overview
Specializations
Myelodysplastic Syndromes with Ring Sideroblasts
Research activity includes treatment of anemia in adults with lower-risk myelodysplastic syndromes, especially those with ring sideroblasts who depend on red blood cell transfusions and have limited response to prior erythropoiesis-stimulating agents.
- Transfusion-dependent anemia
- Red blood cell transfusion independence
- Lower-risk MDS
The sponsor’s work in this area centers on hematologic disease management and the clinical burden of chronic transfusion needs.
Higher-Risk MDS and Oligoblastic AML
Clinical research also addresses patients with higher-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia who are being prepared for allogeneic hematopoietic cell transplantation within a short treatment window.
- Pre-transplant disease control
- Allogeneic HCT
- Acute myeloid leukemia
This area reflects a focus on treatment pathways before transplant in aggressive myeloid malignancies.
Diffuse Large B-Cell Lymphoma
The sponsor funds research in relapsed or primary refractory diffuse large B-cell lymphoma, addressing patients whose disease has not responded adequately to prior therapy and who require second-line treatment options.
- Relapsed DLBCL
- Primary refractory lymphoma
- Salvage therapy
Its lymphoma portfolio is concentrated on aggressive B-cell malignancies with high unmet need in the relapsed setting.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of CPX-351 Versus Conventional Care Regimens Prior to Allogeneic Hematopoietic Cell Transplantation in High-Risk MDS and Oligoblastic AML Patients |  Austria Germany | Not Recruiting |
| Evaluation of Luspatercept Efficacy and Safety in Patients with Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts Requiring Red Blood Cell Transfusions | Austria Germany Spain | Not Recruiting |
| Phase 3 Multicenter Randomized Open‑Label Trial of Efanesoctocog Alfa Intensified Replacement Therapy for Synovitis in Patients with Congenital Hemophilia A | Austria Germany | Not Yet Recruiting |
| Phase III Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Austria Germany Spain | Not Recruiting |
Data & Insights
This sponsor works with 12 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 72 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases4 trials249 other sponsors
Partnered Research Centres
72 centres- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Estrada Clara Campoamor N 341, 36312 Vigo
- Address
- Barranco De La Ballena S N, 35010 Las Palmas de Gran Canaria
- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Johannes-Mueller-Strasse 7, Sued, 56068 Koblenz
Want to get in touch with this sponsor?
Send a question and we'll pass it on to GWT-Tud GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.